Why PAVmed Inc.’s (PAVM) Stock Is Up 5.70%
As of Thursday, May 07, PAVmed Inc.’s PAVM share price has surged by 5.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Commentary & Analysis
Is PAVmed Inc (PAVM) Stock a Good Investment?
Learn more about PAVmed Inc's (PAVM) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Advanced Medical Equipment & Technology stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | PAVM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $20.1 | $389.6 | 10% |
|
| Shares Out (Mil) | 6.3 | 40.9 | 16% |
|
| Institutional Ownership | 25.3% | 82.8% | 11% |
|
| Float (Mil) | 4.1 | 35.5 | 10% |
|
| Beta | 0.52 | 0.85 | 30% |
|
| Avg Daily Volume (000s) | 32 | 298 | 24% |
|
| Price Change (52-week) |
(78.3%) | 63.7% | 8% |
|
| Growth | PAVM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | 15.0% | (5.6%) | 63% |
|
| EPS (5yr) | 55.6% | 10.2% | 95 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (65.3%) | (15.5%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.660) | ($2.330) | ($2.380) | |
| Month Ago EPS | ($0.660) | ($2.330) | ($2.380) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.630) | ($2.620) | ($2.450) | |
| Year/Year Chg | (24.5%) | (58.6%) | na | |
| Financials | PAVM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $141 | 0% |
|
| Net Income (TTM) (Mil) | ($12) | ($9) | 28% |
|
| EPS (TTM) | ($8.693) | ($0.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($2) | 22% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $1 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $17 | $26 | 32% |
|
| Enterprise Value (Q1) (Mil) | $37 | $409 | 14% |
|
| Valuation | PAVM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.58 | 2.73 | 11% |
|
| P/E | na | 25.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | PAVM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (220.5%) | 58.7% | 1% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (28.7%) | (12.2%) | 17% |
|
| ROE | (54.8%) | (10.7%) | 14% |
|
| Liabilities to Assets | 52.0% | 47.2% | 45% |
|
| F-Score | 2 | 4 | 7% |
|
PAVmed Inc. did not pass any screens on 10/2/2026.
